Company intelligence / Profile preview

Shanghai Escugen Biotechnology Co., Ltd.

Shanghai, Shanghai, Chinabloomberg.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Escugen’s lead program ESG401—an anti-TROP2 ADC—has shown positive results in a first-in-human study for patients with locally advanced/metastatic solid tumors. The company has multiple programs advancing through clinical and preclinical development targeting various cancers using proprietary ADC technology platforms. Their EZWi-Fit® platform demonstrates improved efficacy and safety over existing technologies.

Therapeutic areas: OncologyImmunology
Modalities: Antibody-drug conjugates (ADCs)monoclonal antibodiesCAR-T therapiesfusion proteins
Industry: Biotech

Drug pipeline

11 assets

ESG401

10 more assets in the full pipeline.

Request access →

Partnerships

Levena Biopharma/Sorrento Therapeutics – co-development of ESG401 and shared global rights/patents on the productTOT BIOPHARM – strategic collaboration for late-stage development/commercialization of ADC drugs including manufacturing support in China/US/EU marketsForeseen Biotechnology – partnership to develop first-in-class ADCs including FS001 targeting novel antigens; Ipsen licensed global rights to FS001 which uses Escugen’s linker-payload technologyInxMed – license agreement to develop next-generation ADCs

Beyond the preview

Go deeper on Shanghai Escugen Biotechnology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Escugen Biotechnology Co., Ltd..

Explore the full profile